Phaseline

Companies › Extend Biosciences

Extend Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EXT608
Modified parathyroid hormone attached to vitamin D to extend half-life
PTHPhase 2HypoparathyroidismMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06988670EXT608Phase 2HypoparathyroidismMetabolic and endocrineMay 2027

Targets

PTH (1)

Companies with the same targets

–

Companies built like this

Amorphical ERX Pharmaceuticals Hyundai Pharm Rare Thyroid Therapeutics International River 3 Renal

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.